These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11823898)

  • 1. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
    Kasper S
    Psychopharmacology (Berl); 2002 Feb; 159(4):445-6. PubMed ID: 11823898
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin.
    Kasper S; Wolf R
    Eur Neuropsychopharmacol; 2002 Apr; 12(2):119-22. PubMed ID: 11872327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary retention with reboxetine-fluoxetine combination in a young man.
    Benazzi F
    Can J Psychiatry; 2000 Dec; 45(10):936. PubMed ID: 11190365
    [No Abstract]   [Full Text] [Related]  

  • 4. Doxazosin for reboxetine-induced urinary hesitancy.
    Szabadi E
    Br J Psychiatry; 1998 Nov; 173():441-2. PubMed ID: 9926068
    [No Abstract]   [Full Text] [Related]  

  • 5. Reboxetine and hyponatremia.
    Ranieri P; Franzoni S; Trabucchi M
    N Engl J Med; 2000 Jan; 342(3):215-6. PubMed ID: 10651558
    [No Abstract]   [Full Text] [Related]  

  • 6. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
    Künzel HE; Schuld A; Pollmächer T
    Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy.
    Demyttenaere K; Huygens R; Van Buggenhout R
    Int Clin Psychopharmacol; 2001 Nov; 16(6):353-5. PubMed ID: 11712624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound weight loss associated with reboxetine use in a 44-year-old woman.
    Lu TY; Kupa A; Easterbrook G; Mangoni AA
    Br J Clin Pharmacol; 2005 Aug; 60(2):218-20. PubMed ID: 16042676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine for the treatment of patients with Cocaine Dependence Disorder.
    Szerman N; Peris L; Mesías B; Colis P; Rosa J; Prieto A;
    Hum Psychopharmacol; 2005 Apr; 20(3):189-92. PubMed ID: 15799010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depersonalization-derealization syndrome induced by reboxetine.
    Khazaal Y; Zullino DF
    Swiss Med Wkly; 2003 Jul; 133(27-28):398-9. PubMed ID: 12947529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine and treatment-refractory elderly patients with depression.
    Chue P
    Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary Hesitancy Associated With Atomoxetine.
    Gandhi R; Narang P; Lippmann S
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28930379
    [No Abstract]   [Full Text] [Related]  

  • 16. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.
    Sivrioglu EY; Topaloglu VC; Sarandol A; Akkaya C; Eker SS; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):548-50. PubMed ID: 17123681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of reboxetine in bulimia nervosa: a pilot study.
    Fassino S; Daga GA; Boggio S; Garzaro L; Pierò A
    J Psychopharmacol; 2004 Sep; 18(3):423-8. PubMed ID: 15358988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reboxetine: tolerability and safety profile in patients with major depression.
    Tanum L
    Acta Psychiatr Scand Suppl; 2000; 402():37-40. PubMed ID: 10901157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
    Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
    Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.